Better Health for All

Vistagen Therapeutics is a clinical-stage biopharmaceutical company entirely focused on developing new generation medicines for anxiety, depression, and other central nervous system disorders, which are significant unmet medical needs.

Its pipeline includes five clinical-stage product candidates targeting conditions like social anxiety disorder, major depressive disorder, and vasomotor symptoms, aiming to radically improve mental health worldwide. All product candidates have demonstrated favorable safety profiles in clinical studies, with no serious adverse events reported and adverse event profiles comparable to placebo. The company's R&D expenses were $39.4 million in fiscal 2025, and $20.0 million in 2024, but the percentage of R&D budget allocated to health improvement cannot be determined as the total R&D budget is not provided. Vistagen received Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the third consecutive year in 2025, scoring 92% to 100% in an evaluation of workplace culture, benefits, compliance, and wellness programs. The company was also certified as a Great Place to Work® for the second year in a row in 2025. Vistagen takes seriously its legal and regulatory obligations to protect the privacy of all data generated or entrusted to it, implementing reasonable administrative, technical, and procedural safeguards. The company's fasedienol product candidate does not exert effects on cellular receptors associated with drug abuse liability potential, nor does it produce agonistic or antagonistic effects on GABA ion channels. All Vistagen-sponsored studies are designed and conducted in accordance with applicable laws, regulations, and guidelines, as well as recognized ethical standards like GLP, GMP, and GCP, under the oversight of an Independent Review Board or Ethics Committee. The company follows regulations for registering trials and reporting results on sites such as clinicaltrials.gov.

Fair Money & Economic Opportunity

Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, services, pricing, fees, lending compliance, customer financial data, wealth building outcomes, or financial literacy initiatives are not applicable. While the company focuses on underserved populations, this is in the context of medical treatment and mental health, not financial inclusion. Similarly, its diversity and inclusion efforts are internal or related to healthcare access, not financial services.

Honest & Fair Business

Vistagen Therapeutics, Inc. has a Code of Business Conduct, approved in October 2023, which includes a whistle-blower policy.

This policy allows employees to report violations openly or anonymously via a third-party Vistagen Integrity Hotline and includes a non-retaliation commitment. The Code is distributed to and annually acknowledged by all personnel. The company also has an anti-corruption policy that explicitly prohibits bribes, kickbacks, or other improper transfers of value to influence government officials, customers, or healthcare professionals. This policy is also subject to annual acknowledgment by all personnel. For third-party verification, the Vistagen Integrity Hotline is managed by a third party, and Requests For Proposals ask respondents to describe their commitment to diversity and inclusion for their service teams. However, there is no evidence of specific ethical claims being independently verified beyond the third-party hotline.

Kind to Animals

Vistagen Therapeutics utilizes human stem cell-based bioassay systems, such as CardioSafe 3D™ and LiverSafe 3D™, for preclinical safety screening and predictive toxicology.

However, animal studies are still required for preclinical laboratory tests and concurrent with clinical trials, in compliance with FDA Good Laboratory Practice (GLP) regulations. The company states it conducts animal research responsibly, humanely, and ethically. Research and development expenses were approximately $20.0 million in 2024 and $44.4 million in 2023. The company received $8.9 million in funding from the U.S. National Institute of Health for the development of AV-101. The number of animals used annually is not disclosed, but animal studies are a required part of the drug development process.

Planet-Friendly Business

No specific, quantitative data related to planet-friendly business metrics, such as emissions, renewable energy, water usage, waste diversion, or climate targets, was found in the provided articles for Vistagen Therapeutics, Inc.

The articles explicitly state that sustainability data is currently unavailable or that no quantitative environmental, social, or governance (ESG) performance data is provided.

Respect for Cultures & Communities

Vistagen Therapeutics has a formal partnership with The Goldie Hawn Foundation's MindUP program, which is a mental health initiative, not an indigenous or local community group.

The company has no reported cultural appropriation incidents. Its operations are not described as impacting cultural contexts, and there is no evidence of a specific cultural impact assessment protocol. The company's Code of Business Conduct, approved in October 2023, outlines internal reporting channels for personnel, including a third-party Integrity Hotline, but these are standard grievance processes not explicitly community-specific. The Code also states that all personnel receive written information about compliance obligations upon joining and certify compliance annually. While SAMHSA's National Helpline, which Vistagen supports through awareness, is available in English and Spanish, this is not evidence of Vistagen's own products or communications demonstrating language inclusivity. There is no specific cultural incident response framework beyond general internal reporting.

Safe & Smart Tech

Vistagen Therapeutics has reported no material cybersecurity incidents and no incidents of unauthorized data use.

The company implements mandatory user security awareness and training. Its cybersecurity risk management program is designed to comply with NIST Special Publication 800-171 and CMMC level 1. Risk assessments are conducted to identify material cybersecurity risks, and the company engages third-party cybersecurity experts for security assessments. However, the company's privacy policy only mentions the ability to refuse cookies, with no further details on user data access, deletion, or consent. There is no specific information on the frequency of vulnerability patching or the scope of security testing beyond general engagement with third-party experts.

Zero Waste & Sustainable Products

Vistagen Therapeutics, Inc. states it uses hazardous materials and wastes in its research and development, contracting with third parties for their disposal.

The company is committed to complying with all applicable environmental, health, and safety laws and regulations. No specific waste disposal violations or fines are mentioned in the provided documents, indicating no reported violations in the past three years.